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Background.  The risk of progression of latent tuberculosis infection (LTBI) to active disease increases with pregnancy. This 
study determined the prevalence and risk factors associated with LTBI among pregnant women in Uganda.
Methods. We enrolled 261 pregnant women, irrespective of gestational age. Participants who had known or suspected active tu-
berculosis (TB) on the basis of clinical evaluation or who had recently received treatment for TB were excluded. LTBI was defined as 
an interferon-γ concentration ≥0.35 IU/mL (calculated as either TB1 [eliciting CD4+ T-cell responses] or TB2 [eliciting CD8+ T-cell 
responses] antigen minus nil) using QuantiFERON TB Gold-Plus (QFT-plus) assay.
Results. LTBI prevalence was 37.9% (n = 99) (95% confidence interval [CI], 32.3–44.0). However, 24 (9.2%) subjects had indetermi-
nate QFT-plus results. Among participants with LTBI, TB1 and TB2 alone were positive in 11 (11.1%) and 18 (18.2%) participants, respec-
tively. In multivariable analysis, human immunodeficiency virus (HIV) infection (adjusted odds ratio [aOR], 4.4 [95% confidence interval 
{CI}, 1.1–18.0]; P = .04) and age 30–39 years (aOR, 4.0 [95% CI, 1.2–12.7]; P = .02) were independently associated with LTBI. Meanwhile, 
smoking status, alcohol use, nature of residence, crowding index, and TB contact were not associated with LTBI.
Conclusions. Our findings are in keeping with the evidence that HIV infection and advancing age are important risk factors for 
LTBI in pregnancy. In our setting, we recommend routine screening for LTBI and TB preventive therapy among eligible pregnant 
women.
Keywords.  CD4+ T-cell and CD8+ T-cell TB responses; latent tuberculosis infection; pregnancy; risk factors; Uganda.
The World Health Organization (WHO) estimates that 
close to 2 billion people worldwide are latently infected with 
Mycobacterium tuberculosis complex [1, 2]. Latent tuberculosis 
infection (LTBI) manifests as a specific immune response in the 
absence of clinical and radiological disease but with capacity 
to reactivate and cause clinical disease at a later time [1, 2]. In 
fact, an estimated 5%–10% of human immunodeficiency virus 
(HIV)–negative individuals with LTBI progress to active dis-
ease at some point in their life, translating into approximately 
10 million cases progressing to active tuberculosis (TB) cases 
and about 1.4 million deaths every year [3].
Women in their reproductive years, during pregnancy or the 
early postpartum period, are disproportionately affected by TB, 
and TB remains an important cause of death in this group [3]. 
In 2019 alone, 450 000 of the estimated 3.2 million women who 
fell ill with TB died of the disease [3]. The WHO has no specific 
report on active TB in pregnancy. However, a study estimated 
that >200 000 annual cases of active TB disease occur during 
pregnancy globally [4].
TB in pregnancy poses a substantial risk of morbidity to both 
the pregnant woman and the fetus if not diagnosed and treated 
in a timely manner [5]. Immune dysregulation in pregnancy is 
associated with a more insidious onset of active TB, increased 
risk of LTBI, and progression of LTBI to active TB disease [4, 6]. 
Globally, an estimated 900 million women have latent LTBI [4, 6]. 
These women have a considerably increased risk of reactivation 
to active disease during pregnancy or in puerperium [4, 6].
In a recent systematic review, among pregnant women in the 
United States, the prevalence of LTBI ranged from 14% to 48% [6]. 
In this study, the diagnostic performance of both tuberculin skin 
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test (TST) and interferon-gamma (IFN-γ) release assay (IGRA) 
was comparable and was unaffected by pregnancy [6]. However, 
there are limited data and understanding of factors associated with 
LTBI among pregnant women in Africa, a region with a high TB 
and HIV burden. One study from Tanzania found a prevalence of 
LTBI among pregnant women as high as 37.4% [7]. Two studies 
from Ethiopia showed a prevalence of LTBI of 31.9% [8] and 33% 
[9] among pregnant women using IGRA.
IGRAs, such as the QuantiFERON TB Gold-Plus (QFT-
plus) assay, have very high sensitivities and are not influenced 
by prior BCG vaccination [10]. QFT-plus has TB antigens 
that elicit CD4+ T-cell IFN-γ response reflecting a recall from 
reexposure and antigens that elicit CD8+ T-cell IFN-γ induced 
from viable or recent exposure [11].
Uganda is a high-TB-burden country with >30% of reported 
TB cases affecting women [12]. It was estimated that 1400–4400 
pregnant women in Uganda had active TB in 2011 [4], but 
the TB epidemiology has changed considerably since Uganda 
achieved the 2015 TB-related Millennium Development Goals. 
The burden of both active TB and LTBI among pregnant women 
is largely unknown. Therefore, we aimed at determining the 




This was a single-center, antenatal care–based, cross-sectional 
study conducted among pregnant women attending a routine 
antenatal care clinic at Kawempe National Referral Hospital 
(KNRH), Kampala, Uganda. The study was conducted between 
September 2020 and December 2020.
Study Setting
KNRH is an obstetrics and gynecology hospital, and a teaching 
and research center affiliated to the Makerere University College 
of Health Science. It is a 170-bed national referral hospital lo-
cated along the Kampala-Gulu Highway that receives referrals 
mainly from lower health centers in Kampala and neighboring 
districts. The antenatal care clinic at KNRH runs on Tuesday 
through Thursday every week, offering antenatal care services 
to about 50–60 new mothers every clinic day.
Study Population
We enrolled pregnant women who were willing and competent 
to provide informed written consent, regardless of gestational 
age or gravidity. We excluded from the study patients who had 
known or suspected active TB based on the Uganda National 
Intensified TB Case Finding Guide [13] followed by a routine 
physical examination, or who had recently (past 6 months) re-
ceived treatment for TB. Trained study nurses consecutively 
enrolled eligible participants from the daily antenatal care at-
tendance register until the sample size was reached.
Sample Size
Using formula for a single population, we calculated a sample 
size of 260 participants based on an estimated prevalence of 
LTBI of 16.1% as reported in a previous study in the general 
population in Uganda [14], a margin of error of 5%, 20% in-
complete data or withdrawal of consent, and a z statistic at a 
95% confidence interval (CI).
Demographic and Obstetric Data
A study assistant administered a semistructured study question-
naire through a face-to-face interview to collect information 
on maternal characteristics such as age, gravidity, education 
level, occupation, marital status, HIV status and antiretroviral 
therapy (ART), TB contact, gestational age, history of abortion, 
smoking and alcohol usage, and the number of antenatal care 
visits in the current pregnancy. Gestational age was estimated 
using the date of the last normal menstrual period.
Anthropometric Data
Body mass index (kg/m2) and waist-hip ratio (cm) were cal-
culated following anthropometric measurements. Specifically, 
weight was measured with minimal clothing and without shoes 
using a digital bathroom weighing scale (SECA-Germany) and 
height was measured with a stadiometer (Fazzini S208 height 
rod). The weighing scale was calibrated on a daily basis. The 
waist and hip circumferences were measured using a tailor’s 
measuring tape. The brachial blood pressure (BP) was meas-
ured on both arms using a MEDQUIP arm-type fully auto-
matic digital blood pressure monitor (model BP-2400) with an 
appropriate adult cuff size and the participant seated upright in 
a comfortable position after resting. BPs were taken 5 minutes 
apart and the average of the 2 measurements was considered as 
the participant’s BP.
IGRA
A study nurse drew blood for IGRA directly into the IGRA 
tubes. The IGRA assay, QuantiFERON-TB Gold-plus 
(Qiagen, Hilden, Germany) was performed according to 
the manufacturer’s instructions [11]. All samples were pro-
cessed and ran in a clinical laboratory at the Department of 
Immunology and Molecular Biology, School of Biomedical 
Sciences, Makerere University, which is 30 minutes away 
from KNRH. In brief, 1 mL of blood was drawn directly into 
4 separate heparinized tubes: the nil control (containing only 
heparin), the mitogen control (containing phytohemagglu-
tinin), TB1 (containing M.  tuberculosis–specific antigens 
ESAT-6 and CFP-10 modified for eliciting CD4+ T-cell re-
sponses), and TB2 (containing M.  tuberculosis–specific 
antigens ESAT-6 and CFP-10 modified for eliciting CD8+ 
T-cell responses). Immediately after filling each tube, the 
tube was inverted at least 10 times to allow the blood to coat 
the entire wall. Within 2 hours of venipuncture, the tubes 
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were remixed by inverting them again 10 times before im-
mediately being placed in an incubator set at 37°C. After 24 
hours of incubation, the tubes were centrifuged at 3000g and 
the plasma was collected using single wrapped 3-mL Pasteur 
pipettes. The amount of IFN-γ in the plasma was measured 
by enzyme-linked immunosorbent assay (ELISA) with the re-
agents included in the test kit according to the manufacturer’s 
recommendations. In brief, 50 µL of working-strength con-
jugate was added to each well of the QFT-Plus ELISA plate, 
followed by 50 µL of the plasma and standards to the appro-
priate wells. The plate was incubated for 2 hours in the bio-
safety cabinet at room temperature. The plates were washed 
at least 6 times and an allowance of 5 seconds of soak time 
with 400 µL of 1X wash buffer using an ELISA washer. Next, 
100 µL of the substrate solution was added and the plate was 
incubated at room temperature for 30 minutes. Last, 50 µL of 
substrate solution was added and the plate was immediately 
read using an ELISA reader at 450 nm with a reference wave-
length of 620 nm to obtain optical densities. Results were cal-
culated using QFT-Plus analysis software version 2.71.2 [11].
Definitions
LTBI was defined as an IFN-γ concentration ≥0.35 IU/mL 
(calculated as either TB1 or TB2 antigen minus nil) per the 
manufacturer’s guideline [11]. If antigen-nil was <0.35 IU/mL 
or <25% of the nil value, when the mitogen was ≥0.5 IU/mL, 
the result was considered negative. If (1) nil was >8 IU/mL or 
(2) antigen-nil ≥0.35 IU/mL and <25% of the nil value when 
the nil was ≤8.0 IU/mL and the mitogen was <0.5 IU/mL, the 
results were considered indeterminate.
Statistical Methods
We used Stata version 16 software (StataCorp, College Station, 
Texas) to perform all statistical analyses. Categorical variables 
were expressed as frequencies and percentages. For all numer-
ical variables, Shapiro-Wilk normality test was completed to 
select an appropriate test. Normally distributed data were sum-
marized as mean and standard deviations and nonnormally 
distributed data as median and interquartile range (IQR). The 
χ 2 or Fisher exact test was used to assess for associations be-
tween LTBI and categorical variables while Mann–Whitney U/
Student t tests and Wilcoxon-signed rank/analysis of variance 
were used to assess for associations between LTBI and contin-
uous variables (age, blood pressure, weight, age, gestational age, 
and height, waist, and hip circumferences). All variables with 
P < .2 in the bivariate analyses were fitted into a multivariate lo-
gistic regression model to adjust for potential confounders such 
as age, parity, gestational age, and HIV status. Multivariable 
logistic regression model was used to assess for independent 
predictors of LTBI among the study participants. Results were 
presented as odds ratios (ORs) and 95% CIs. All analyses were 
2-tailed and P < .05 was considered significant at 95% CI. 
Graphs were prepared using GraphPad Prism version 8.0.2 soft-
ware (GraphPad, La Jolla, California)
Patient Consent Statement
All participants provided informed written consent after the 
study procedure, risks, and benefits were explained to them. 
The study protocol was approved by the Makerere University 
School of Medicine Ethics and Research Committee (reference 
number 2020–113). All principles of research involving human 




A total of 261 pregnant women met the inclusion criteria. Table 1 
summarizes the characteristics of the recruited participants. 
The median age of the participants was 26 (IQR, 23.0–30.0) 
years. The majority of mothers were married (86.2%) and had 
reported for their first antenatal care visit (75.9%). Up to 99% 
(n = 258) of the participants were in the second trimester with a 
median gestational age at enrollment of 26 (IQR, 20–31) weeks. 
About 11.1% had history of TB contact with family members. 
Thirteen (5%) participants reported that they were HIV pos-
itive. All HIV-positive women were on ART and had not re-
ceived TB preventive therapy.
QuantiFERON-TB Gold-Plus Results
Overall, 99 (37.9%) participants had a positive QFT-plus result. 
Of these, TB1 and TB2 alone were positive in 11 (11.1%) and 
18 (18.2%) participants, respectively (Figure 1). Twenty-four 
(9.2%) and 138 (52.9%) participants had indeterminate and 
negative QFT-plus results, respectively. Considering indetermi-
nate results as negative, the overall prevalence of LTBI preva-
lence was 37.9% (n = 99) (95% CI, 32.3%–44.0%).
Overall, the interreliability of QFT-Plus assay for TB1 vs 
TB2 was moderate (agreement = 88.9%, κ = .75; P < .0001). In 
subanalysis, there was also moderate interreliability agreement 
between TB1 and TB2 among HIV-negative pregnant mothers 
(agreement = 89.5%, κ = .75; P < .0001), but this was weak for 
HIV-positive clients (agreement = 76.9%, κ = .49; P = .036).
There was a strong positive correlation between IFN-γ 
value in TB1 and TB2 (Pearson coefficient  =  0.88; P < .0001; 
Figure 2).
The quantitative IFN-γ value in TB2 was similar to that in 
TB1 irrespective of HIV status (TB1: 2.7 ± 3.4 [HIV positive, 
n = 13] vs 1.4 ± 2.7 IU/mL [HIV negative, n = 248], P = .2; 
TB2: 1.9 ± 2.5 [HIV positive, n = 13] vs 1.3 ± 2.5 IU/mL 
[HIV negative, n = 248], P = .4 (Figure 3A). However, parti-
cipants with BCG scars had higher values compared to those 
without (TB1: 1.4 ± 2.7 [BCG scar, n = 177] vs 0.7  ±  1.9 IU/
mL [no BCG scar, n = 84], P = .003; TB2: 1.3 ± 2.4 [BCG scar, 
n = 177] vs 0.6 ± 1.7 IU/mL [no BCG scar, n = 84], P = .002) 
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(Figure 3B). There was no statistically significant difference be-
tween mitogen and nil levels across HIV status (mitogen: 9.4 
IU/mL [HIV positive] vs 7.3 IU/mL [HIV negative], P = .85; 
nil: 0.24 IU/mL [HIV positive] vs 0.15 IU/mL [HIV negative], 
P = .26).
Risk Factors for LTBI Among Participants
On bivariate analysis (Table 2), LTBI was associated with 
advancing age (P < .001) and HIV status (P = .006). BCG 
scar (P = .259), smoking status (P = .433), nature of resi-
dence (P = .707), crowding index (P = .433), and TB contact 
(P = .302) were not significantly associated with LTBI status.
On multivariable logistic regression (Table 3), pregnant 
women in their third decade of life (30–39 years of age) were 
4 times more likely to have LTBI compared to teenagers (ad-
justed OR [aOR], 3.96 [95% CI, 1.23–12.73]; P = .021). In ad-
dition, participants with HIV were also 4 times more likely 
to have LTBI (aOR, 4.37 [95% CI, 1.06–18.04]; P = .041) than 
HIV-negative women.
TB1 = 81 TB2 = 88
11 70 18
(TB1 u TB2)' = 162
Σ = 261
Figure 1. QuantiFERON-TB Gold-plus results of the participants. Abbreviations: 
TB1, CD4+ T-cell tuberculosis response; TB2, CD8+ T-cell tuberculosis response.
Table 1. Baseline Characteristics of Participants (N = 261)
Participant Characteristics No. (%)
Antenatal visit at enrollment
 First 198 (75.9)
 Second 36 (13.8)
 Third 7 (2.7)
 Fourth or more 20 (7.7)
Age, y, median (IQR) 26 (23.0–30.0)
Age group  
 15–19 20 (7.7)
 20–29 161 (61.7)
 30–39 77 (29.5)
 40–49 3 (1.2)
Marital status
 Married 225 (86.2)
 Single 36 (13.8)
Education level
 Informal 4 (1.5)
 Primary 59 (22.6)
 Secondary 151 (57.9)
 Tertiary 47 (18.0)
Occupational status
 Unemployed 119 (45.6)
 Business 80 (30.7)
 Professional 34 (13.0)
 Skilled worker 24 (9.2)
 Unskilled worker 4 (1.5)
Smoking status
 Former 1 (0.4)
 Never 260 (99.6)
Alcohol usage
 Current 29 (11.1)
 Former 38 (14.6)
 Never 194 (74.3)
Family history of diabetes
 No 218 (83.5)
 Yes 43 (16.5)
Residence
 Urban 217 (84.4)
 Rural 40 (15.6)
HIV status
 Negative 248 (95.0)
 Positive 13 (5.0)
BCG scar
 Yes 177 (67.8)
 No 84 (32.2)
Family history of TB
 No 232 (88.9)
 Yes 29 (11.1)
TB contact
 No 244 (93.5)
 Yes 17 (6.5)
Crowding index
 ≤4 household occupants 196 (75.1)
 ≥5 household occupants 65 (24.9)
Gravidity
 Primigravida 89 (34.1)
 Multigravida 154 (59.0)
 Grand multigravida 18 (6.9)
Participant Characteristics No. (%)
Previous abortion
 No 217 (83.1)
 Yes 44 (16.9)
Gestational age at enrollment, wk, median (IQR) 26 (20–31)
Trimester at enrollment
 1 1 (0.4)
 2 258 (98.9)
 3 2 (0.8)
Anthropometry, median (IQR)
 BMI, kg/m2 27.2 (23.7–31.4)
 Waist-hip ratio, cm 0.91 (0.86–0.96)
Blood pressure at enrollment, median (IQR)
 Systolic, mm Hg 122.5 (114.0–131.0)
 Diastolic, mm Hg 76.5 (71.5–84.0)
Data are presented as No. (%) unless otherwise indicated.
Abbreviations: BMI, body mass index; HIV, human immunodeficiency virus; IQR, interquar-
tile range; TB, tuberculosis.
Table 1. Continued
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DISCUSSION
Routine antenatal care visit provides a unique opportunity to 
identify pregnant women with LTBI and facilitate further eval-
uation and follow-up as needed. In the present study, we found 
that about 38% of pregnant women attending antenatal care at a 
tertiary hospital in Uganda had LTBI, using IGRA. Our findings 
suggest that pregnant women who had HIV infection and those 
aged 30 years or older were 4-fold more likely to have LTBI. Our 
finding is congruent with similar studies from Tanzania [7] and 
Ethiopia [9] which found a prevalence of LTBI of 37.4% and 
33% among pregnant women, respectively. In 2 systematic re-
views, LTBI was reported in about 33% of women in the Middle 
East and North Africa [15] and among 14%–48% of pregnant 
women in the United States [6]. Interesting, we showed that 
participants with BCG scars had much higher IFN-γ concen-
tration, reflecting the immunomodulatory effect of BCG in 
LTBI. BCG revaccination may be further investigated in this 
population.
A few prior studies looked into LTBI prevalence in the general 
and special populations in Uganda. Two observational studies 
conducted in Uganda found the prevalence of LTBI to be 16.1% 
among adolescents and 49.0% among the general adult pop-
ulation [14, 16]. Both studies used TST to demonstrate LTBI 
status, which has a relatively lower diagnostic accuracy than 
IGRA in populations that have high BCG vaccination coverage 
[10]. Another study investigated household contacts of TB pa-
tients in Uganda [17]. The prevalence of LTBI in this study was 

















Figure 2. Correlation of quantitative interferon-γ values in TB1 and TB2 tubes. 
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Figure 3. Quantitative interferon-γ value in TB1 and TB2 tubes stratified by HIV status (A) and presence or absence of a BCG scar (B). Abbreviations: HIV, human immuno-
deficiency virus; IFN-γ, interferon gamma; TB1, CD4+ T-cell tuberculosis response; TB2, CD8+ T-cell tuberculosis response.
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in western Uganda who are engaged in hazardous alcohol use, 
the prevalence of LTBI based on TST positivity was reported at 
35% [18]. In this study, the prevalence of LTBI among women 
was 33.9%.
Pregnancy is characterized by immunological changes 
that may predispose or increase TB reactivation [6]. Immune 
dysregulation in pregnancy, mainly driven by a surge in serum 
progesterone levels, is marked by an anti-inflammatory mi-
lieu characterized by quantitative and qualitative defects in 
circulating CD4+ and CD8+ T cells with a corresponding 
increase in the number of circulating regulatory T cells [19]. 
This dysregulation dampens the proinflammatory immune re-
sponse, often by producing interleukin 10 (IL-10). Furthermore, 
progesterone also induces the placenta to produce IL-10, [20] 
which suppresses cell-mediated Th1 cytokines (IFN-γ, IL-2, 
Table 3. Multivariable Logistic Regression Model Showing Factors 
Associated With Latent Tuberculosis Among Study Participants
Variables Adjusted OR (95% CI) P Value
Age category, y 
 15–19 Reference   
 20–29 1.4 (.5–4.1) .580
 30–39 4.0 (1.2–12.7) .021
Alcohol usage
 Never Reference   
 Former 1.0 (.5–2.3) .928
 Current 0.8 (.3–1.9) .595
HIV status
 Negative Reference   
 Positive 4.4 (1.1–18.0) .041
Gravidity
 Primigravida Reference   
 Multigravida 0.9 (.47–1.57) .632
 Grand multigravida 0.4 (.11–1.5) .173
Abbreviations: CI, confidence interval; HIV, human immunodeficiency virus; OR, odds ratio.
Table 2. Factors Associated With Latent Tuberculosis Infection Among 
Study Participants
Participant Characteristics LTBI No LTBI P Value
Antenatal care visit at enrollment
 First 74 (74.8) 124 (76.5) .919
 Second 15 (15.2) 21 (13)  
 Third 2 (2) 5 (3.1)  
 Fourth or more 8 (8.1) 12 (7.4)  
Age group, y
 15–19 5 (5.1) 15 (9.3) <.001
 20–29 49 (49.5) 112 (69.1)  
 30–39 42 (42.4) 35 (21.6)  
 40–49 3 (3) 0 (0)  
Marital status
 Married 86 (86.9) 139 (85.8) .808
 Single 13 (13.1) 23 (14.2)  
Education level
 Informal 3 (3) 1 (0.6) .164
 Primary 27 (27.3) 32 (19.8)  
 Secondary 51 (51.5) 100 (61.7)  
 Tertiary 18 (18.2) 29 (17.9)  
Occupational status 
 Unemployed 39 (39.4) 80 (49.4) .335
 Business 34 (34.3) 46 (28.4)  
 Professional 13 (13.1) 21 (13)  
 Skilled worker 10 (10.1) 14 (8.6)  
 Unskilled worker 3 (3) 1 (0.6)  
Smoking status
 Former 0 (0) 1 (0.6) .433
 Never 99 (100) 161 (99.4)  
Alcohol usage
 Current 9 (9.1) 20 (12.4) .113
 Former 20 (20.2) 18 (11.1)  
 Never 70 (70.7) 124 (76.5)  
Residence
 Rural 16 (16.7) 24 (14.9) .707
 Urban 80 (83.3) 137 (85.1)  
HIV status
 Negative 89 (89.9) 159 (98.2) .006
 Positive 10 (10.1) 3 (1.9)  
BCG scar
 No 36 (36.4) 48 (29.6) .259
 Yes 63 (63.6) 114 (70.4)  
Family history of TB
 No 90 (90.9) 142 (87.7) .417
 Yes 9 (9.1) 20 (12.4)  
TB contact
 No 95 (96) 149 (92) .302
 Yes 4 (4) 13 (8)  
Crowding index
 ≤4 household members 77 (77.8) 119 (73.5) .433
 ≥5 household members 22 (22.2) 43 (26.5)  
Gravidity
 Primigravida 39 (39.4) 50 (30.9) .193
 Multigravida 56 (56.6) 98 (60.5)  
 Grand multigravida 4 (4) 14 (8.6)  
Previous abortion
 No 86 (86.9) 131 (80.9) .209
 Yes 13 (13.1) 31 (19.1)  
Participant Characteristics LTBI No LTBI P Value
Gestational age at enroll-
ment, wk, median (IQR)
26 (20–32) 25.9 (19.7–30.6) .962
Trimester at enrollment
 1 1 (1) 0 (0) .054
 2 96 (97) 162 (100)  
 3 2 (2) 0 (0)  
Anthropometry, median (IQR)
 BMI, kg/m2 27.1 (23.2–30.9) 27.5 (24.0–31.8) .174
 Waist-hip ratio, cm 0.9 (0.9–1.0) 0.9 (0.9–1.0) .238
Blood pressure at enrollment, median (IQR) 
 Systolic, mm Hg 123 (114–131) 122 (115–131) .589
 Diastolic, mm Hg 77 (70.5–84.5) 76 (72–84) .896
Data are presented as No. (%) unless otherwise indicated.
Abbreviations: BMI, body mass index; HIV, human immunodeficiency virus; IQR, interquar-
tile range; LTBI, latent tuberculosis infection; TB, tuberculosis.
Table 2. Continued
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tumor necrosis factor–α) [21]. Consequently, pregnant women 
are at higher risk of acquiring both primary TB disease (from 
recent TB infection) and progression of LTBI to active disease 
compared to nonpregnant women [22].
Active TB is more likely during pregnancy and the early 
postpartum period than any other time in a woman’s life [23]. 
Therefore, women of reproductive age are suffering dispropor-
tionate morbidity and mortality due to TB. TB in pregnancy is 
associated with poor outcomes, including increased mortality 
in both the neonate and the pregnant woman [4]. In our study, 
HIV infection was found in 13 participants, of whom 10 (77%) 
had LTBI, and HIV infection was independently associated 
with LTBI. This finding is consistent with published case series, 
which shows that the risk of TB in HIV-infected pregnant 
women appears to be higher, with 1%–11% developing active 
TB during pregnancy or the early postpartum period [22, 24]. 
However, recent work has shown that despite the high TB in-
cidence among HIV-positive individuals, detection of LTBI 
among these individuals is lower [8]. In Africa, WHO estimates 
revealed that TB rates are up to 10 times higher in pregnant 
women living with HIV than in pregnant women without HIV 
infection [3].
Similar to our study, Sheriff et al [7] in Tanzania reported that 
parity, body mass index, gestational age, and HIV serostatus were 
not associated with LTBI among pregnant women. However, in 
contrast, we found a significant association between age and 
HIV infection with LTBI among our participants. Notably, 
Sheriff et al used TST for the diagnosis of LTBI and 3 different 
cutoffs were considered in classifying participants as having 
LTBI, whereas we used IGRA. Additionally, almost 30% of the 
study participants (significantly younger women) were lost to 
follow-up. This could explain the differences with our study.
Currently, there is no gold-standard diagnostic tool for the 
diagnosis of LTBI. TST or IGRA, both of which screen for im-
munological memory, are the most common screening tools in 
clinical practice [25]. IGRA is specific for M. tuberculosis while 
there is cross-reactivity with nontuberculous mycobacterial in-
fections when using TST or in those who previously received 
BCG vaccine, hence a false positive [25]. QFT-plus, an IGRA 
platform used in the present study, has M. tuberculosis–specific 
antigen that triggers both CD4+ and CD8+ T-cell responses [11]. 
Whereas positivity of both TB1-nil and TB2-nil indicates LTBI, 
TB2 tube response can be associated with active or subclinical 
TB disease and/or recent TB infection [26]. In our study, up to 
18.2% of the participants had an isolated positive response to 
TB2 antigens, suggestive of possible acquisition of M. tubercu-
losis infection during pregnancy or subclinical TB disease.
Our study has limitations. Participants were derived from a 
single center, so our findings may not be generalizable. Second, we 
had a high number of patients who had indeterminate QFT-plus, 
and it is likely we may have underestimated the true burden of 
LTBI in this population. Moreover, 21 of 24 (88%) indeterminate 
results were due to low mitogen, indicating a dampened immune 
response. Third, the cross-sectional design did not allow us to 
prospectively look for whether CD8+ women were more likely to 
develop active TB disease (which would support subclinical dis-
ease) and we were unable assess for prior exposure (which would 
support recent exposure). Fourth, we were unable to obtain a 
complete detail of ART regimens, including duration, current 
viral load, and CD4+ T-cell count for HIV-positive participants. 
However, we used the QFT-plus assay, which is a more specific 
test for M. tuberculosis infection than the TST. To the best of our 
knowledge, this is the first study to report on the prevalence of 
LTBI among pregnant women in Uganda. We recommend future 
studies to prospectively evaluate maternal and fetal outcomes in 
a population of LTBI vs non-LTBI mothers. Also, studies looking 
at determinants of other important risk factors for LTBI progres-
sion such as diabetes mellitus and chronic kidney disease among 
pregnant women are welcome. Last but not least, the high burden 
of LTBI and TB2 in this population merits active TB investigation 
and TB preventive therapy.
In conclusion, we report a high prevalence of LTBI among 
pregnant women in Uganda, especially those with HIV infec-
tion and those with advanced age. These findings suggest a need 
for strategies to scale up LTBI screening among high-risk preg-
nant women and TB preventive treatment in this population to 
advance progress toward TB elimination.
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